TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 9% of the time (803 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: coronarystablepressuremm hgdl
  Phrases that lowered it: metformindailywith typeand safetytype diabetes
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 10.9% (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Phase: 3 (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 238 (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 71 (lowers risk) · Sponsor's track record
• Number of arms: 3 (lowers risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Keywords listed: 1 (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 0 (raises risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes NCT01834274 · started 2013 · scored riskier than 40% of active trials terminated
• Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes NCT01481116 · started 2012 · scored riskier than 92% of active trials terminated
• Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes NCT01829477 · started 2013 · scored riskier than 52% of active trials terminated
• Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus NCT01414920 · started 2011 · scored riskier than 98% of active trials completed
• Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes NCT01456195 · started 2011 · scored riskier than 99% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.